Rothschild & Co Redburn cut shares of Moderna (NASDAQ:MRNA – Free Report) from a neutral rating to a sell rating in a research note released on Thursday morning, MarketBeat.com reports. Rothschild & Co Redburn currently has $81.00 price objective on the stock, up from their previous price objective of $40.00.
Several other brokerages have also recently issued reports on MRNA. UBS Group cut Moderna from a “hold” rating to a “sell” rating in a research note on Thursday. Piper Sandler reiterated an “overweight” rating on shares of Moderna in a research report on Monday, August 3rd. Deutsche Bank Aktiengesellschaft began coverage on shares of Moderna in a report on Friday, August 28th. They issued a “hold” rating on the stock. Jefferies Financial Group reissued a “hold” rating on shares of Moderna in a research report on Wednesday, August 19th. Finally, Argus upgraded shares of Moderna from a “hold” rating to a “buy” rating and set a $180.00 price objective for the company in a research note on Friday, August 28th. Seven research analysts have rated the stock with a Buy rating, twelve have assigned a Hold rating and five have issued a Sell rating to the company. Based on data from MarketBeat, the company has an average rating of “Hold” and an average price target of $76.72.
Read Our Latest Research Report on Moderna
Moderna Price Performance
Moderna (NASDAQ:MRNA – Get Free Report) last issued its earnings results on Friday, July 31st. The company reported ($1.97) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($2.03) by $0.06. The company had revenue of $145.00 million during the quarter, compared to analyst estimates of $102.93 million. Moderna had a negative return on equity of 28.30% and a negative net margin of 141.43%.The firm’s quarterly revenue was up 2.1% on a year-over-year basis. During the same quarter last year, the business posted ($2.13) EPS. As a group, equities research analysts forecast that Moderna will post -6.09 earnings per share for the current year.
Insiders Place Their Bets
In other Moderna news, President Stephen Hoge sold 53,336 shares of the company’s stock in a transaction dated Monday, June 15th. The shares were sold at an average price of $51.37, for a total value of $2,739,870.32. Following the completion of the transaction, the president owned 1,483,848 shares in the company, valued at approximately $76,225,271.76. This represents a 3.47% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Shannon Klinger sold 3,471 shares of the company’s stock in a transaction dated Tuesday, September 1st. The stock was sold at an average price of $139.95, for a total transaction of $485,766.45. Following the completion of the transaction, the insider owned 74,129 shares of the company’s stock, valued at approximately $10,374,353.55. This trade represents a 4.47% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. 10.80% of the stock is currently owned by insiders.
Institutional Inflows and Outflows
Several large investors have recently made changes to their positions in the business. MUFG Securities EMEA plc purchased a new stake in shares of Moderna during the second quarter worth about $28,000. Allied Private Wealth LLC purchased a new stake in Moderna during the 2nd quarter worth approximately $30,000. Canton Hathaway LLC acquired a new position in shares of Moderna during the first quarter valued at approximately $31,000. Archer Investment Corp purchased a new position in shares of Moderna in the second quarter valued at approximately $36,000. Finally, EverSource Wealth Advisors LLC lifted its position in shares of Moderna by 148.3% in the second quarter. EverSource Wealth Advisors LLC now owns 1,341 shares of the company’s stock valued at $37,000 after acquiring an additional 801 shares in the last quarter. 75.33% of the stock is owned by institutional investors and hedge funds.
Key Headlines Impacting Moderna
Here are the key news stories impacting Moderna this week:
- Positive Sentiment: Moderna and Merck reported that the Phase 3 INTerpath-001 trial of intismeran autogene plus Keytruda met its primary recurrence-free-survival endpoint in resected stage IIB–IV melanoma. It was the first positive Phase 3 result for an mRNA-based cancer therapy and strengthens Moderna’s long-term oncology outlook, although detailed data have not yet been released. Moderna melanoma trial article
- Positive Sentiment: Technical analysts describe the recent consolidation as a potential bullish pennant following the cancer-vaccine-driven breakout. Elevated short interest could provide additional buying pressure if the shares break above resistance. Moderna technical forecast
- Neutral Sentiment: Chief Legal Officer Shannon Klinger sold 3,471 shares for approximately $486,000 under a pre-arranged Rule 10b5-1 plan to cover tax withholding tied to vested equity awards. Because the transaction was planned and tax-related, it provides limited insight into management’s view of Moderna’s valuation.
- Negative Sentiment: Rothschild & Co. Redburn downgraded Moderna from Neutral to Sell, saying the cancer-vaccine rally has made the stock overvalued. The firm raised its price target to $81 from $40, but the new target remains well below recent trading levels, intensifying profit-taking concerns. Rothschild Moderna downgrade
- Negative Sentiment: GSK is advancing an mRNA influenza vaccine toward Phase 3 after reporting stronger immune responses in Phase 2. The competing program could challenge Moderna’s newly approved mFlusiva and increase pressure on its commercial vaccine pipeline. GSK mRNA flu vaccine competition
About Moderna
Moderna, Inc is a biotechnology company headquartered in Cambridge, Massachusetts, specializing in messenger RNA (mRNA) therapeutics and vaccines. The company’s platform leverages synthetic mRNA to instruct cells to produce proteins that can prevent or treat diseases. Since its founding in 2010, Moderna has advanced from early-stage research into a broad pipeline of vaccine and therapeutic candidates designed to address infectious diseases, rare genetic disorders and chronic illnesses.
Moderna’s flagship product is its mRNA-based COVID-19 vaccine, which was the first of its kind to receive emergency use authorization and later full approval in multiple jurisdictions.
Featured Articles
- Five stocks we like better than Moderna
- Zscaler’s Strong Quarter Still Left Investors Waiting on 1 Key Signal
- Is Duolingo the Next Netflix-Style Comeback Story?
- GitLab’s AI Tools Are Starting to Turn Developer Demand Into Real Revenue
- GTA VI’s Console Problem Isn’t Take-Two’s Problem
Receive News & Ratings for Moderna Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Moderna and related companies with MarketBeat.com's FREE daily email newsletter.
